TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $10 from $11 and keeps a Hold rating on the shares. The firm said with 4Q positively preannounced, focus was on the guide and Akoya Biosciences (AKYA) update. The sales guidance was below consensus but managementreiterated enthusiasm for its merger with Akoya.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Buy Rating Affirmed for Quanterix Amid Strong Q4 Performance and Strategic Merger with Akoya Biosciences
- Quanterix price target lowered to $15 from $20 at Canaccord
- Quanterix Reports Strong Revenue Growth and Strategic Expansion
- Quanterix: Hold Rating Amid Short-Term Challenges and Long-Term Opportunities
- Quanterix reports Q4 EPS (30c) vs (23c) last year